XM
PDLI

XTX Markets’s PDL BioPharma, Inc. PDLI Stock Holding History

XTX Markets’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,699
Closed -$43K – 227
2020
Q2 		$43K Buy
+14,699
New +$46.5K 0.15% 124
2020
Q1 		– Sell
-21,655
Closed -$70K – 157
2019
Q4 		$70K Buy
+21,655
New +$62.9K 0.49% 57

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

XTX Markets's PDLI Position: Q3 2020 in Review

XTX Markets sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 14,699 shares — an estimated $43K sold.

XTX Markets first reported a position in PDLI in Q4 2019 and held it in 2 quarters. The position peaked at $70K in Q4 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • XTX Markets reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • XTX Markets sold 14,699 PDL BioPharma, Inc. shares in Q3 2020, an estimated $43K.
  • XTX Markets first reported a position in PDL BioPharma, Inc. in Q4 2019 and held it in 2 quarters.
  • XTX Markets's PDL BioPharma, Inc. position peaked at $70K in Q4 2019.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on XTX Markets's 13F filing for Q3 2020, filed 29 Oct 2020.